THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS

Bibliographic Details
Main Authors:	Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, Kaplan, R
Format:	Conference item
Published:	2010

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
by: Adams, R, et al.
Published: (2009)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
by: Madi, A, et al.
Published: (2010)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
by: Maughan, T, et al.
Published: (2009)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
by: Adams, R, et al.
Published: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Maughan, T, et al.
Published: (2011)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Adams, R, et al.
Published: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
by: Adams, R, et al.
Published: (2009)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
by: Adams, R, et al.
Published: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
by: Maughan, T, et al.
Published: (2010)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
by: Wasan, H, et al.
Published: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
by: Adams, R, et al.
Published: (2008)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
by: Smith, C, et al.
Published: (2013)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
by: Smith, C, et al.
Published: (2010)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
by: Wood, G, et al.
Published: (2017)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
by: Maughan, T, et al.
Published: (2010)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
by: Dae-Won Lee, et al.
Published: (2019-05-01)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
by: Seymour, M, et al.
Published: (2007)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
by: Madi, A, et al.
Published: (2018)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
by: Moe, M, et al.
Published: (2008)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
by: Madi, A, et al.
Published: (2017)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
by: Akari Hashimoto, et al.
Published: (2014-05-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
by: Seymour, M, et al.
Published: (2007)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
by: Yeong Hak Bang, et al.
Published: (2021-03-01)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
by: Seymour, M, et al.
Published: (2011)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
by: West, H, et al.
Published: (2018)

Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
by: Ching-Wen Huang, et al.
Published: (2021-07-01)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
by: S Whyte, et al.
Published: (2010-10-01)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
by: Cheadle, J, et al.
Published: (2010)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
by: Iveson, T, et al.
Published: (2018)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
by: Gray, V, et al.
Published: (2019)

Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients
by: Xianwei Mo, et al.
Published: (2020-01-01)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol
by: Antonio Avallone, et al.
Published: (2020-08-01)

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
by: Si-wei Zhou, et al.
Published: (2012-01-01)

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
by: Wen-Kuan Huang, et al.
Published: (2022-08-01)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
by: Mitra, S, et al.
Published: (2001)

Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy
by: Masier Sara, et al.
Published: (2004-03-01)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
by: Vale, C, et al.
Published: (2012)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS

Similar Items

Similar Items